Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2022.1118572 Oncology Correction Corrigendum: TGF-β1 promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial-mesenchymal transition Li Zi-Xiong 1 2 † Chen Jie-Xin 1 † Zheng Ze-Jun 1 † Cai Wang-Jing 1 † Yang Xiong-Bin 1 Huang Yuan-Yuan 1 Gong Yao 3 Xu Feng 4 Chen Yong-Song 5 * Lin Ling 1 3 * 1 Department of Rheumatology and Immunology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China 2 Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China 3 Department of Rheumatology, Shantou University Medical College, Shantou, China 4 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, China 5 Department of Endocrinology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China

Edited and Reviewed by: Donghong Zhang, Emory University, United States

*Correspondence: Ling Lin, llinc@163.net; Yong-Song Chen, yongsongchen@126.com

†These authors have contributed equally to this work

This article was submitted to Breast Cancer, a section of the journal Frontiers in Oncology

 10 01 2023 2022 12 1118572 07 12 2022 12 12 2022 Copyright © 2023 Li, Chen, Zheng, Cai, Yang, Huang, Gong, Xu, Chen and Lin 2023 Li, Chen, Zheng, Cai, Yang, Huang, Gong, Xu, Chen and Lin

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on TGF-β1 promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial-mesenchymal transition. by Li Z-X, Chen J-X, Zheng Z-J, Cai W-J, Yang X-B, Huang Y-Y, Gong Y, Xu F, Chen Y-S and Lin L (2022) Front. Oncol. 12:1051148. doi: 10.3389/fonc.2022.1051148 TGF-β1 EndMT angiogenesis breast cancer BCSLC dorsal skinfold window chamber

Error in Figure/Table

In the published article, there was an error in Figure 1 High expression of MVD predicted unfavorable prognosis of IDC patients. as published. In Figure 1B , the title of X axis was “Specificity”, it should be corrected to “1-Specificity”. The corrected Figure 1 High expression of MVD predicted unfavorable prognosis of IDC patients. and its caption appear below.

High expression of MVD predicted unfavorable prognosis of IDC patients. (A) Representative images of immunohistochemical (IHC) staining of vWF and CD34 in samples from breast invasive ductal carcinoma (IDC) patients. (B) ROC curve of the CD34 and vWF by the DFS of IDC patients. (C, D) Kaplan-Meier analysis of DFS and OS of IDC patients from our cohort by vWF and CD34.

In the published article, there was an error in Figure 2 MVD level is positively correlated with EndMT markers in breast cancer. as published. In Figure 2A, B , the red “#” and green “*” were missing. The corrected Figure 2 MVD level is positively correlated with EndMT markers in breast cancer. and its caption appear below.

MVD level is positively correlated with EndMT markers in breast cancer. (A, B) Representative images of double-IHC staining of vWF, CD34 (brown, with red “#”) and either α-SMA, FSP-1 or Vimentin (red, with green “*”) in samples from IDC patients. (C–G) Kaplan-Meier analysis of DFS and OS of IDC patients from our cohort by α-SMA, FSP-1, Vimentin, VE-Cadherin and Fibronectin.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.